Skip to main content
. 2020 Nov;20(6):535–540. doi: 10.7861/clinmed.2020-0506

Table 2.

Presenting symptoms and comorbidities in patients with pancreatic exocrine insufficiency, and results of adjusted univariable analysis of their association with initiation of PERT and clinical response

Variable Patients with PEI, n=182, n (%) Association with initiation of PERT, OR (95% CI)a Association with clinical response to PERT, OR (95% CI)a
Presenting symptoms
 Abdominal pain 91 (50.0) 1.30 (0.70–2.40) 1.01 (0.29–3.50)
 Diarrhoea 126 (69.2) 0.78 (0.40–1.49) 0.79 (0.21–3.00)
 Weight loss 84 (46.2) 1.60 (0.85–3.01) 6.83 (1.23–37.93)b
 Steatorrhoea 31 (17.0) 2.54 (1.06–6.09)b 2.94 (0.57–15.23)
 Bloating 37 (20.3) 1.11 (0.52–2.36) 0.47 (0.13–1.75)
 Flatulence 6 (3.3) 0.30 (0.05–1.74) 0.04 (0.002–0.93)b
Comorbidities
 Chronic pancreatitis 21 (11.5) 4.13 (1.31–13.02)b 3.06 (0.34–27.66)
 Pancreatic cancer 5 (2.75) 3.97 (0.42–37.29) n/a
 Upper GI surgery 16 (8.79) 1.37 (0.47–4.04) 0.22 (0.04–1.16)
 Diabetes mellitus 64 (35.2) 2.21 (1.11–4.42)b 0.54 (0.14–2.07)
Alcohol excess
 Previous 25 (18.5) 3.18 (1.04–9.71)b 0.68 (0.11–4.34)
 Current 27 (20.0) 1.47 (0.56–3.88) 4.52 (0.36–56.73)
Smoking
 Previous 24 (18.3) 0.73 (0.27–2.01) 4.39 (0.19–102.25)
 Current 44 (35.6) 1.43 (0.60–3.38) 1.10 (0.20–6.11)

Reference categories for alcohol excess and smoking are ‘never’.

a = adjusted for age, sex and ethnicity;

b = p<0.05; CI = confidence interval; GI = gastrointestinal; n/a = not applicable; OR = odds ratio; PEI = pancreatic exocrine insufficiency; PERT = pancreatic enzyme replacement therapy.